TV Drug Ads Must Not Gloss Over Side Effects

The FDA is currently debating whether to require a toll-free number and web address on all TV drug ads so we can easily report serious side effects to the agency.

But the FDA commissioner wants to study the idea for two more years. That’s too long! Prescription drug ads in magazines and newspapers already have this reporting information. Why not TV?

The benefits of making it easy to report serious drug side effects are clear:

  • Better reporting of side effects will help the FDA do a better job of detecting dangerous drugs on the market sooner. Dangers often emerge only after millions of people start taking a drug.
  • A recent poll found that only 7 percent knew how to report serious side effects to the FDA.
  • The toll-free number and web address is already required in print drug ads; this would only put it on TV ads, so more consumers would see it.

An FDA panel convened recently to hear testimony on this, but now they need to hear from you. Please take a minute to tell the FDA panel why it’s important they require a toll-free number and web address on all TV drug ads now!

Subject: Docket No. FDA-2008-N-0226 - Include safety reporting information on all DTC drug ads

To: The FDA

I support adding a 1-800 number and web address to TV ads for prescription drugs so people can report serious side effects.

The FDA should make it as easy as possible for the public to report serious drug side effects, so it can better track safety problems with drugs on the market. I urge you to require all TV drug ads include a toll-free number and website so consumers can easily report their serious drug side effects to the FDA, and to include this information as soon as possible.

[Your Comments]

Sincerely,

[Your Name]
[Your Address]
Sign Petition
Sign Petition
You have JavaScript disabled. Without it, our site might not function properly.

Privacy Policy

By signing, you accept Care2's Terms of Service.
You can unsub at any time here.

Having problems signing this? Let us know.